Related Experiment Video
Updated: Apr 4, 2026
Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease
Angela Pyle1, Rebecca Brennan1, Marzena Kurzawa-Akanbi1
1Mitochondrial Research Group, University of Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom.
Abstract:
The identification of cell-free circulating mitochondrial DNA (ccf-mtDNA) in early-stage Alzheimer's disease (AD) raised the possibility that the same neurodegenerative effect could be observed in Parkinson's disease (PD). Here, and for the first time, we investigated the role of ccf-mtDNA in PD, identifying a significant reduction of ccf-mtDNA in PD patient cerebrospinal fluid (CSF) when compared to controls. Our data demonstrates that CSF ccf-mtDNA is not only a powerful biomarker for PD, but, given that the effect is also observed in AD, is likely a biomarker for neurodegeneration.
Insights
Researchers found lower levels of cell-free circulating mitochondrial DNA (ccf-mtDNA) in Parkinson's disease (PD) patients' cerebrospinal fluid (CSF). This discovery suggests ccf-mtDNA could be a biomarker for PD and neurodegeneration.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Cell-free circulating mitochondrial DNA (ccf-mtDNA) has been identified in Alzheimer's disease (AD).
- This finding prompted investigation into its potential role in other neurodegenerative conditions like Parkinson's disease (PD).
Purpose of the Study:
- To investigate the role and diagnostic potential of ccf-mtDNA in Parkinson's disease (PD).
- To determine if ccf-mtDNA levels in cerebrospinal fluid (CSF) differ between PD patients and healthy controls.
Main Methods:
- Analysis of ccf-mtDNA levels in the cerebrospinal fluid (CSF) of Parkinson's disease (PD) patients.
- Comparison of CSF ccf-mtDNA concentrations between PD patients and a control group.
Main Results:
- A significant reduction in ccf-mtDNA was observed in the CSF of PD patients compared to controls.
- These findings indicate that CSF ccf-mtDNA is a potential biomarker for PD.
Conclusions:
- Reduced CSF ccf-mtDNA is a characteristic finding in Parkinson's disease (PD).
- ccf-mtDNA in CSF may serve as a general biomarker for neurodegeneration, as observed in both PD and AD.
